Abbott Laboratories
ABT
$90.62
+2.20%
Abbott Laboratories is a global healthcare leader that manufactures and markets a diversified portfolio of medical devices, diagnostic equipment, nutritional products, and branded generic pharmaceuticals. The company is a dominant player across its core segments, particularly in cardiovascular devices and continuous glucose monitoring, and derives roughly 60% of its sales from international markets. The current investor narrative is dominated by a significant stock price decline following a cut to its 2026 profit guidance, which has overshadowed solid quarterly earnings, creating a debate between near-term headwinds and the long-term value proposition of its resilient business model and its 54-year history of dividend growth.…
ABT
Abbott Laboratories
$90.62
Related headlines
Investment Opinion: Should I buy ABT Today?
Rating & Thesis: Hold. Abbott presents a compelling long-term value proposition clouded by significant near-term uncertainty; investors should wait for evidence of stabilization before committing new capital. This is consistent with the underlying 'Buy' ratings from analysts who are betting on a recovery, but the price action suggests the market needs more proof.
Supporting Evidence: The forward P/E of 14.55x is reasonable and suggests the market has priced in headwinds. Revenue growth remains positive at 4.4% YoY with steady sequential progression. Profitability is robust, with a Q4 gross margin of 57.05% and operating margin of 19.64%. Finally, the exceptional $7.40B in TTM free cash flow and low 0.29 debt-to-equity ratio provide a substantial margin of safety and support the dependable dividend.
Risks & Conditions: The two biggest risks are a breakdown below the $82 support level, confirming the downtrend, and another earnings guidance reduction. This Hold would upgrade to a Buy if the stock demonstrates sustained support above $85 while showing sequential margin improvement and reaffirming (or raising) guidance. It would downgrade to a Sell if revenue growth decelerates below 2% or if the forward P/E expands above 18x without corresponding earnings growth. Relative to its own history and the forward earnings outlook, the stock appears fairly valued to slightly undervalued, but not deeply so.
Sign up to view all
ABT 12-Month Price Forecast
The data paints a picture of a high-quality company experiencing a painful but likely transient de-rating. The fundamentals—cash flow, balance sheet, market position—remain intact, but the technical and sentiment damage is severe. The forward valuation is compelling, but it requires patience as the stock is not yet showing definitive signs of a bottom. The stance is neutral with a bias toward eventual recovery, but confidence is medium due to the lack of a clear near-term catalyst. An upgrade to bullish would require a confirmed breakout above the $116 resistance level on strong volume; a downgrade to bearish would be triggered by a sustained break below the $81.97 low.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Abbott Laboratories's 12-month outlook, with a consensus price target around $117.81 and implied upside of +30.0% versus the current price.
Average Target
$117.81
9 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
9
covering this stock
Price Range
$73 - $118
Analyst target range
Analyst coverage for Abbott appears limited in the provided data, with only 9 analysts cited for EPS estimates, and no explicit consensus price target, recommendation distribution, or target range is available in the dataset. The institutional ratings data shows a series of reiterations from major firms like Citigroup, Barclays, and RBC Capital maintaining 'Buy' or 'Outperform' ratings throughout early 2026, even as the stock price fell, indicating underlying analyst confidence in the long-term thesis. The lack of a clear consensus target and range suggests either incomplete data or that coverage is focused on estimates rather than price targets; however, the maintained bullish ratings from multiple firms in the face of negative price action signal that analysts view the decline as an overreaction to temporary guidance issues, not a fundamental deterioration.
Bulls vs Bears: ABT Investment Factors
The investment debate for Abbott Laboratories is a classic clash between near-term sentiment and long-term fundamentals. The bear case, driven by a severe technical breakdown and a guidance cut that has shattered investor confidence, currently holds stronger immediate evidence, as reflected in the stock's 35% annual decline. However, the bull case is underpinned by a fortress balance sheet, strong cash generation, and a forward P/E that appears to discount the bad news. The single most important tension is whether the 2026 guidance cut represents a temporary setback in an otherwise resilient business model or the beginning of a more protracted period of earnings pressure. The resolution of this tension, visible in upcoming quarterly execution against the lowered bar, will determine the stock's direction.
Bullish
- Strong Financial Fortress: Abbott maintains a robust balance sheet with a low debt-to-equity ratio of 0.29 and a healthy current ratio of 1.58. This financial strength supports its 409th consecutive quarterly dividend and provides flexibility for strategic moves like the Exact Sciences acquisition.
- Attractive Forward Valuation: The stock's forward P/E ratio of 14.55x is reasonable for a high-quality healthcare conglomerate, suggesting the market has priced in near-term headwinds. This represents a significant discount to the trailing P/E of 33.55x, implying expectations for an earnings recovery.
- Solid Revenue Growth Trajectory: Q4 2025 revenue grew 4.4% YoY to $11.46B, with a clear sequential progression from $10.36B in Q1. The Medical Devices segment, at $5.68B, remains a primary and substantial growth driver.
- Exceptional Free Cash Flow Generation: The company generated $7.40B in trailing twelve-month free cash flow. This substantial cash generation underpins shareholder returns and strategic investments, providing a margin of safety.
Bearish
- Severe Technical Downtrend: The stock is down 35.38% over the past year and 29.71% over six months, trading 37% below its 52-week high. Despite a modest 5.19% one-month bounce, it remains in a clear bearish phase, significantly underperforming the S&P 500.
- Elevated Trailing P/E Multiple: The trailing P/E of 33.55x is elevated and sits above the median of its historical range. This indicates that despite the sharp price decline, earnings have contracted more rapidly, preventing the valuation from reaching a historical low.
- Profit Guidance Cut Overshadows Results: Recent news highlights that a cut to 2026 profit guidance has overshadowed a solid Q1 earnings beat. This creates a significant near-term overhang and signals investor concern about headwinds, as reflected in the stock's sharp decline post-announcement.
- Net Margin Compression: Q4 2025 net margin compressed to 15.5% from an inflated 84.1% in Q4 2024. While the prior year was boosted by a large tax benefit, the current margin reflects normalized, albeit still healthy, profitability that faces pressure.
ABT Technical Analysis
The stock is in a pronounced and sustained downtrend, with a 1-year price change of -35.38% and a 6-month decline of -29.71%. As of the latest close at $88.18, the price is trading near the lower end of its 52-week range, approximately 11% above the 52-week low of $81.97 and 37% below the 52-week high of $139.06, indicating the stock is deeply oversold and may represent a value opportunity, though it remains in a clear bearish phase. Recent momentum shows a modest short-term recovery attempt, with a 1-month gain of 5.19%, which contrasts sharply with the severe 3-month loss of -18.37%; this divergence suggests a potential oversold bounce or consolidation, but it has yet to challenge the dominant downtrend, as evidenced by the stock's significant underperformance relative to the S&P 500, which is up 22.86% over the past year. Key technical support is clearly defined at the 52-week low of $81.97, while resistance looms at the 52-week high of $139.06; a sustained breakdown below $82 would signal a continuation of the downtrend, while a move above the recent high near $116 would be needed to suggest a reversal. The stock's beta of 0.62 indicates it is 38% less volatile than the broader market, which historically provided defensive characteristics but has not shielded it from this severe idiosyncratic sell-off.
Beta
0.62
0.62x market volatility
Max Drawdown
-40.2%
Largest decline past year
52-Week Range
$82-$139
Price range past year
Annual Return
-32.4%
Cumulative gain past year
| Period | ABT Return | S&P 500 |
|---|---|---|
| 1m | +7.3% | +1.5% |
| 3m | -16.5% | +13.4% |
| 6m | -27.6% | +10.9% |
| 1y | -32.4% | +24.5% |
| ytd | -27.0% | +10.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ABT Fundamental Analysis
Revenue growth remains positive but has decelerated, with Q4 2025 revenue of $11.46 billion representing a 4.4% year-over-year increase; however, the sequential trend from Q1 to Q4 2025 shows revenue climbing from $10.36B to $11.46B, indicating steady quarterly progression. The Medical Devices segment is the primary growth driver, contributing $5.68 billion in the latest period, significantly larger than Nutritional Products at $1.94 billion and Established Pharmaceuticals at $1.38 billion. The company is highly profitable, with Q4 2025 net income of $1.78 billion and a robust gross margin of 57.05%; operating margins have been stable in the high-teens, with the Q4 operating margin at 19.64%, though net margin compressed to 15.5% in Q4 from an elevated 84.1% in Q4 2024, which was inflated by a large tax benefit. Abbott's balance sheet and cash flow are exceptionally strong, with a conservative debt-to-equity ratio of 0.29, a healthy current ratio of 1.58, and substantial free cash flow generation of $7.40 billion on a trailing twelve-month basis; this financial fortress supports the company's 409th consecutive quarterly dividend and provides ample flexibility for strategic investments like the acquisition of Exact Sciences.
Quarterly Revenue
$11.5B
2025-12
Revenue YoY Growth
+0.04%
YoY Comparison
Gross Margin
+0.57%
Latest Quarter
Free Cash Flow
$7.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ABT Overvalued?
Given Abbott's consistent profitability, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is elevated at 33.55x, while the forward PE is significantly lower at 14.55x; this wide gap reflects both a depressed current EPS and the market's expectation for a substantial earnings recovery in the coming year. Compared to sector averages, Abbott's trailing PE of 33.55x and Price-to-Sales (PS) ratio of 4.94x are not directly comparable without a provided industry benchmark, but the forward PE of 14.55x appears reasonable for a high-quality healthcare conglomerate, suggesting the market has already priced in significant near-term challenges. Historically, the stock's own trailing PE has ranged from approximately 5.3x (post-tax benefit in Q4 2024) to over 46x in recent years; the current 33.55x multiple sits above the median of its historical range, indicating that despite the sharp price decline, the valuation is not at a historical low because earnings have contracted more rapidly, leaving the stock trading at a premium to its own average earnings multiple.
PE
33.6x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 5x~46x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Abbott's primary financial risk is not leverage or liquidity, given its strong balance sheet, but rather earnings volatility and margin pressure. The net margin compression from 84.1% to 15.5% year-over-year, while partly due to a non-recurring tax benefit, highlights earnings sensitivity. A more concrete risk is the company's dependence on its Medical Devices segment (nearly 50% of Q4 revenue) for growth; any regulatory setback or competitive loss in this area would disproportionately impact results. Furthermore, with 60% of sales international, the company faces currency translation and geopolitical risks that could pressure reported growth.
Market & Competitive Risks: The most pressing market risk is valuation compression. Despite the price drop, the trailing P/E of 33.55x is elevated historically, and the PS ratio of 4.94x is not cheap. If growth decelerates further, these multiples could contract toward sector averages, applying additional downward pressure on the share price. The stock's low beta of 0.62 has not provided defense during this idiosyncratic sell-off, questioning its traditional 'safe haven' status. Competitive risks are ever-present in medical technology, particularly in high-growth areas like continuous glucose monitoring where innovation cycles are rapid.
Worst-Case Scenario: The worst-case scenario involves a failure to stabilize earnings, leading to a second guidance cut or a significant miss in the Medical Devices segment. This could trigger a wave of analyst downgrades from their currently bullish stance, eroding the last pillar of support. Combined with a broader market downturn, this could force a re-rating to a deeper valuation trough. Realistic downside could see the stock testing and breaking its 52-week low of $81.97, representing a further -7% decline from the current $88.18. A more severe bear case, aligning with the maximum drawdown of -40.21%, could imply a fall toward the $78-$80 range, resulting in a total loss of -10% to -12% from current levels.
FAQ
The key risks are: 1) Execution/Guidance Risk: Failure to meet the already-lowered 2026 profit targets could trigger another sell-off. 2) Vational Compression Risk: The elevated trailing P/E of 33.55x could contract further if growth disappoints. 3) Segment Concentration Risk: Nearly half of revenue comes from Medical Devices; a slowdown here would disproportionately hurt results. 4) Technical Risk: The stock is in a confirmed downtrend, down 35% over the past year, and a break below $82 support could lead to further declines.
The 12-month forecast is bifurcated, with a 50% probability base case target range of $100-$115, a 30% probability bull case target of $125-$139, and a 20% probability bear case target of $82-$95. The base case, which is most likely, assumes the company meets its revised guidance, leading to a slow, grinding recovery as confidence gradually rebuilds. The key assumption behind this scenario is that revenue growth stabilizes in the low-to-mid single digits and margins do not deteriorate further. The wide range reflects the high uncertainty following the guidance cut.
ABT's valuation sends mixed signals. On a trailing basis, the P/E of 33.55x appears elevated relative to its own history. However, the forward P/E of 14.55x is much more reasonable and suggests the market expects a significant earnings recovery. Compared to sector averages (not provided), the Price-to-Sales of 4.94x is not cheap. Overall, the stock appears fairly valued to slightly undervalued based on forward earnings expectations, but it is not deeply discounted. The valuation implies the market expects mid-single-digit growth and stable margins, but is skeptical of any upside surprises.
ABT is a good stock for patient, long-term investors seeking a quality healthcare name at a reasonable forward valuation, but it is not a clear-cut buy for everyone. The forward P/E of 14.55x is attractive, and the 35% decline from highs prices in significant pessimism. However, the stock remains in a strong downtrend and faces near-term execution risk on its lowered guidance. It is a good buy for investors who believe the company's fundamental strengths—its balance sheet, cash flow, and market positions—will ultimately prevail over temporary headwinds, and who can tolerate potential further volatility.
ABT is unequivocally suitable for long-term investment, not short-term trading. Its low beta of 0.62, 54-year dividend growth history, and resilient business model are hallmarks of a long-term compounder. The current volatility is driven by a specific near-term event (guidance cut), which long-term investors can look through. Short-term traders face significant headwinds from the entrenched downtrend and lack of a clear catalyst for a swift reversal. A minimum holding period of 3-5 years is recommended to allow the fundamental story and investor sentiment to realign.
